The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).
 
Maria Gonzalez
No Relationships to Disclose
 
Alexander Christopher Jonathan van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Sydney Ch'ng
No Relationships to Disclose
 
Kerwin Frank Shannon
No Relationships to Disclose
 
Andrew John Spillane
No Relationships to Disclose
 
Jonathan Stretch
No Relationships to Disclose
 
Michael Alexander Rtshiladze
Stock and Other Ownership Interests - Polynovo (I)
 
Thomas Pennington
No Relationships to Disclose
 
David Coker
No Relationships to Disclose
 
Robyn P.M. Saw
Honoraria - BMS GmbH & Co. KG; Merck Sharp & Dohme; Novartis; Qbiotics
Consulting or Advisory Role - MSD; Qbiotics
Speakers' Bureau - Bristol-Myers Squibb/Sanofi; Novartis
Research Funding - Qbiotics
 
Rony Kapoor
No Relationships to Disclose
 
Edward Hsiao
No Relationships to Disclose
 
Robert V Rawson
Honoraria - MSD
 
Monica Osorio
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Serigne N Lo
No Relationships to Disclose
 
Richard A Scolyer
Employment - Sydney Local Health District / Royal Prince Alfred Hospital
Leadership - Melanoma Institute Australia
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; IO Biotech; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; Tour de Cure
 
Angela M Hong
Stock and Other Ownership Interests - BeiGene
Consulting or Advisory Role - Roche (I); Telix Pharmaceuticals
Travel, Accommodations, Expenses - Roche (I)
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
 
Ines Esteves Domingues Pires Da Silva
Consulting or Advisory Role - MSD; MSD